Drug intelligence / Profile preview

LTM1201AZ

Development stage: Unknown
Lead developer: Brigham and Women's Hospital
Modality: Small Molecules
Administration: Oral

Overview

LTM1201AZ is an investigational drug being studied for the treatment of obstructive sleep apnea (OSA). It is part of a group of related compounds (including LTM1201AT, LTM1201AD, and LTM1201AG) evaluated in clinical trials to assess their effects on upper airway muscle function and OSA severity when administered before bedtime. The precise mechanism of action, chemical structure, and pharmacological class have not been disclosed in public sources as of June 2025. The drug is currently under investigation in a clinical trial led by Brigham and Women's Hospital targeting older adults with moderate to severe OSA[2][3]. No information about its molecular target or detailed pharmacology has been published.

Beyond the preview

Go deeper on LTM1201AZ.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LTM1201AZ.

Explore the full profile